Neil Unmack is a Reuters Breakingviews Associate Editor based in London. He covers credit markets, hedge funds, and Italy. Previously he was a corporate finance reporter at Bloomberg News in London. He started his career as a financial journalist in 2001 at Euromoney Institutional Investor, where he covered structured finance for EuroWeek magazine. He was educated at Eton College and Oxford University, graduating with a first class degree in modern languages.
Securities used to finance environmentally friendly investments are thriving, with everyone from JPMorgan to Germany charging in. Yet the $800 bln market does not necessarily mean greener issuers. As investors get better at differentiating, green bonds could become redundant.
People with diabetes are more vulnerable to Covid-19. Now the UK is giving patients free shakes to help them lose weight. Evidence that slimmer waistlines and healthy living can beat the disease is good news; less so for drugmakers that sell $48 bln of insulin and other drugs.
Thermo Fisher Scientific scrapped a bid for German diagnostics group Qiagen after investors balked. The takeover was tabled in March, but the offer looked low once Covid-19 hopes boosted testing groups’ valuations. The U.S. company’s retreat suggests insiders are less gung-ho.